Dec 12 (Reuters) - Alzheimer's trials testing Novo Nordisk’s blockbuster GLP-1 drug semaglutide, despite their failure, underscore a shift to approaching the brain-wasting disease as a system of ...
FILE PHOTO: A scientist looks at hypometabolic and hypoperfusion patterns at the single-subject level from a patient suffering from Alzheimer's disease at the Memory Centre at the Department of ...
Drug-delivering aptamers that can precisely target leukemia stem cells with enhanced potency have been developed. Delivering anticancer drugs with specificity and potency to cancer stem cells is an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback